HC Wainwright Estimates Precigen’s Q1 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) – Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Precigen in a research report issued on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn ($0.03) per share for the quarter, up from their previous estimate of ($0.05). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.02) EPS.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.09. The business had revenue of $4.57 million for the quarter, compared to the consensus estimate of $8.29 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.

A number of other equities analysts have also commented on PGEN. Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a research note on Saturday. Citizens Jmp lifted their price target on Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Finally, Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.50.

Precigen Stock Performance

PGEN stock opened at $3.67 on Monday. The business has a fifty day moving average price of $4.08 and a 200 day moving average price of $3.97. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 2.83. Precigen has a fifty-two week low of $1.11 and a fifty-two week high of $5.47. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.74 and a beta of 1.10.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Precigen by 216.9% during the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 43,245 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 9,043 shares during the last quarter. Strs Ohio acquired a new stake in Precigen in the first quarter worth about $70,000. Geode Capital Management LLC increased its position in Precigen by 7.7% in the second quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock worth $5,325,000 after purchasing an additional 269,580 shares during the period. Finally, Creative Planning raised its holdings in Precigen by 127.8% during the 2nd quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 52,901 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.